Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
cAMP-dependent protein kinase catalytic subunit alpha (PRKACA), also known as the catalytic subunit alpha of protein kinase A (PKA), is a key serine/threonine kinase that plays a central role in the cyclic AMP (cAMP) signaling pathway. Under physiological conditions, PRKACA exists as an inactive tetrameric holoenzyme complexed with regulatory subunits; upon cAMP binding, the catalytic subunits are released to phosphorylate a wide array of downstream substrates involved in glucose metabolism, cell proliferation, and cardiovascular function. Somatic gain-of-function mutations in PRKACA (such as L206R) lead to constitutive, cAMP-independent activation, driving cortisol-producing adrenocortical adenomas and Cushing's syndrome. Furthermore, a recurrent chromosomal deletion on chromosome 19 fuses PRKACA with DNAJB1, producing the oncogenic DNAJB1-PRKACA fusion kinase that drives fibrolamellar hepatocellular carcinoma (FL-HCC). Therapeutic strategies targeting PRKACA include highly selective, ATP-competitive small-molecule inhibitors (such as BLU2864, BLU0588, and DS89002333) and neoantigen-targeting peptide vaccines designed to elicit T-cell responses against the DNAJB1-PRKACA fusion protein. However, because PKA is ubiquitously expressed and regulates vital cellular processes, developing PRKACA-targeted therapies presents significant safety challenges, particularly regarding potential cardiovascular and metabolic toxicities.
ATP-competitive kinase inhibition of the catalytic subunit of protein kinase A, or active immunotherapy targeting the DNAJB1-PRKACA fusion neoantigen
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cAMP-dependent protein kinase catalytic subunit alpha (PRKACA).